Patrick Blanchard MD said:Essentially, current cardiology practice falls short in early diagnosis of atherosclerosis,
although few cardiologists will admit it.
Quoted message said:Utility of annual carotid intima media thickness (CIMT) evaluations cannot be overemphasized,
especially considering how much is known about the origin and progression of "hardening of the
arteries". Endorsed by the American Heart Association, no other test can precisely and safely
measure the progression and regression of atherosclerosis like CIMT. CIMT evaluations provide a
solid foundation for individualization of atherosclerosis management. Without a precise
measurement of atherosclerosis, you are left with guesswork; what should your treatment goals be?
How aggressive in traditional risk factor management should you be? What level of treatment cost
and complication rate should you endure? How do you know if your treatment program is working to
reverse the atherosclerosis you currently have?
I am with you regarding the importance of measuring atherosclerosis, but is CIMT adequate?
My father reported to me that his doctor said that his carotids were something like 35th percentile
for blockage, meaning that they were less blocked than 65% (of those in his age group, I guess).
After some angina and against my advice he had angiography, which found significant blockages in the
smaller coronary arteries, apparently a surprise given the condition of his carotids. Since then I
found the following abstract.
Can somebody remark about the expense and efficacy of electron beam tomography plaque imaging?
Quoted message said:Prog Cardiovasc Dis. 2003 Sep-Oct;46(2):149-70. Related Articles, <ncbi.nlm.nih.govncbi.nlm.nih.govOpen ↗
/entrez/query.fcgi?db=PubMed&cmd=Display&dopt=pubmed_pubmed&from_uid=14505289> Links
<http://www.ncbi.nlm.nih.gov/#>
Click here to read <http://www.us.elsevierhealth.com/cgi-" rel="ugc nofollow noopener">ncbi.nlm.nih.govfref.fcgiOpen ↗
bin/retrieve/pii/S0033062003000847> *Translating tomographic plaque imaging into treatment:
interventional lipidology.*
*Hecht HS.*
Beth Israel Medical Center, New York, NY 10003, USA.
In the context of the beneficial effects of statins, irrespective of the low-density
lipoprotein cholesterol level (LDL-C) in the Heart Protection Study and the relatively poor
event reduction (24%-37%) in the LDL-C reduction trials, electron beam tomography plaque
imaging has provided the necessary data to support a reorientation of traditional treatment
paradigms. The prognostic superiority of calcified plaque quantitation to conventional risk
factor assessment and the poor correlation between pretreatment standard lipid values and
amount of plaque in individual patients, as well as between post treatment lipid changes and
changes in calcified plaque burden, suggest the following: (1) significant calcified plaque
shifts the asymptomatic patient from primary to secondary prevention status;
(2) "abnormal" lipid values in individual patients are best defined by the level at which
atherosclerosis develops; (3) non LDL-C disorders contribute to CAD and should be
identified and treated;
(4) plaque burden, rather than plasma lipid values, should be the target of therapy; and (5)
adequacy of therapy is best evaluated with serial plaque imaging. Other treatment
applications of plaque imaging include triage of patients for stress testing and evaluation
of stress test results.
Publication Types:
* Review
* Review, Tutorial
PMID: 14505289 [PubMed - indexed for MEDLINE]
------------------------------------------------------------------------